Navigation Links
Laureate Biopharma Names James D. Utterback to Board of Directors
Date:4/3/2012

PRINCETON, N.J., April 3, 2012 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc. a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of James D. Utterback to the company's Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20120214/PH53290LOGO )

"Jim is an invaluable addition to our board, and we are fortunate to have access to his deep industry knowledge," said Michael A. Griffith, Chief Executive Officer.

"Jim has more than 30 years of leadership experience building successful startups and public organizations in healthcare software, products and services globally. He has consistently innovated new approaches to growth and his customer-driven business philosophies complement Laureate's quality-focused right-first-time model."

Mr. Utterback most recently served as President, Chief Executive Officer and Board Member of M2Gen, part of the Moffitt Cancer Center in Tampa, Florida, and the third largest oncology academic medical research center in the U.S. He is Founder and Chairman of RxCeL Partners LLC, a healthcare consulting firm based in Philadelphia and Tampa. Mr. Utterback also held positions as Chief Executive Officer of SCIREX Corporation (now Premier Research), and President of the Pharmaceutical Division of Vivo Metrics, a global leader in ambulatory data collection. Earlier in his career, he was a Corporate Officer at Sanofi (then RPR) in Paris, France, and at Covance in Princeton, NJ. Mr. Utterback started his career at GE's Medical Systems Division. He earned a Master of Science in Industrial Psychology from Virginia Polytechnic Institute, and a Bachelor of Science in Psychology/Economics from Washington & Lee University.

About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical co
'/>"/>

SOURCE Laureate Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Laureate Pharma to Add More Manufacturing Capacity
2. Laureate Announces Manufacturing Agreement with Tolerx
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
6. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
7. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
8. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
9. Laureate Pharma Elects New Board Member
10. Thomson Reuters Predicts Nobel Laureates
11. Laureate Pharma Welcomes Three New Members to Business Development Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at ... Institute (TGen) in Phoenix, AZ , ... detection and treatments for patients with a broad range of ... to new clinical trials and access to technology to drive ... bench to bedside across Baylor Scott & White ...
(Date:5/21/2015)... Seventh Wave Laboratories, a consulting-based contract ... pharmaceutical products and medical devices, announced the purchase of ... 50,000 sq. ft. building more than three times the ... Facility renovations will begin immediately and the gradual transition ... in September. , “We are excited about this ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3
... Contaminations of cell cultures show severe problems in the research ... turns here particularly to the prevention , ... that develop substances for therapeutic applications ... focus., Endotoxins (Lipopolysaccharides, LPS) are biologically active, ...
... Amino Acids, RP-HPLC, Precolumn derivatisation, o-Phthalaldehyde (OPA), 2-Mercaptopropionic acid, ... Introduction: , ... light in the UV/visible spectrum. In order to increase sensitivity, ... the amino acids react with a precursor to yield ...
... and specific PCR on any thermal cycler , ... unrivaled performance of , HotStarTaq Plus DNA Polymerase with ... thermal cycler. , , ... Ultrafast hot-start PCR time savings of up to 75%, ...
Cached Biology Technology:Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 2Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 4Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 5Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 6Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 7ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 2ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 3QIAGEN Fast Cycling PCR Kit 2QIAGEN Fast Cycling PCR Kit 3QIAGEN Fast Cycling PCR Kit 4
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... For Immediate Release The Scripps Research Institute and ... Medicine have been awarded approximately $7.5 million over five ... drug candidates for the treatment of nicotine dependence, and ... million will go to Scripps Research, $2.5 million to ...
... of Guelph researchers have finally figured out why female ... nothing to do with genes and everything to do ... "Their behaviour is overwhelmingly influenced by opportunity," said ... professor Andrew McAdam and a team of researchers from ...
... what goes missing in human cells when the gene that ... Johns Hopkins scientists have discovered a potential strategy for therapy. ... snippets known as microRNAs is dramatically reduced in human pancreatic ... a study published Dec. 15 in Genes and Development ...
Cached Biology News:Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 2Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 3Opportunity leads to promiscuity among squirrels, study finds 2Missing molecules hold promise of therapy for pancreatic cancer 2Missing molecules hold promise of therapy for pancreatic cancer 3
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Recombinant Rat Fas Ligand/TNFSF6...
Biology Products: